Company profile for Zedira

NEW Drugs in Dev.: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Zedira is a privately held, clinical stage biopharmaceutical company specialized in transglutaminase. Zedira’s drug candidate ZED1227 was the first transglutaminase blocker ever tested in clinical trials. The peptidomimetic compound showed proof-of-concept in a phase 2a study in celiac disease patients. In addition, ZED1227 has a placebo-like safety profile. For the first time, a transglutaminase is clinically validated...
Zedira is a privately held, clinical stage biopharmaceutical company specialized in transglutaminase. Zedira’s drug candidate ZED1227 was the first transglutaminase blocker ever tested in clinical trials. The peptidomimetic compound showed proof-of-concept in a phase 2a study in celiac disease patients. In addition, ZED1227 has a placebo-like safety profile. For the first time, a transglutaminase is clinically validated as druggable target.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Roesslerstrasse 83 D-64293 Darmstadt
Telephone
Telephone
+49 6151 66628-19
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty